Drug resistance analysis of Escherichia coli isolated from urinary tract infection in elder patients

doi:10.3969/j.issn.1673-8640.2015.12.010

Abstract

Abstract:

Objective To analyze the drug resistance of Escherichia coli isolated from urinary tract infection in elder patients, in order to give a reference for the reasonable selection of antibiotics in clinical treatment.Methods From August 2011 to July 2014, a retrospective analysis was undergone regarding the drug resistance of Escherichia coli isolated from urinary tract infection in 837 elder inpatients (above 60 years old). A total of 17 kinds of antibiotics were determined singly or combinedly for their antimicrobial susceptibility. The drug resistance was analyzed according to the standard of the Clinical and Laboratory Standards Institute (CLSI) issued in 2010. WHONET 5.4 software was used in datum analysis. Results Escherichia coli was 100.0% sensitive to imipenem and meropenem. A significant sensitivity was observed for amikacin, amoxicillin-clavulanic acid and piperacillin-clavulanic acid (drug resistance rate<17.0%), whereas a considerable sensitivity was observed for cefoxitin and netilmicin (drug resistance rate was 30.0%). Less sensitivity was found for gentamicin, tobramycin, compound sulfamethoxazole, ticarcillin-clavulanic acid and the 2nd to 4th generations of cephalosporin antibiotics (drug resistance rate>49.0%). Penicillins, the 1st generation of cephalosporin and ciprofloxacin were almost inactive to Escherichia coli (drug resistance rate>83.0%). Extended-spectrum beta-lactamases (ESBLs)-producing isolates were found with increasing trend regarding 3 statistical years, but there was no statistical significance (P>0.05). Conclusions Escherichia coli displays different levels of drug resistance to different antibiotics. It may hold as a basis in the individual clinical treatment to patients.

Key words: Escherichia coli, Drug resistance analysis, Urinary tract infection, Elder patient

CLC Number:

R378.2

JIANG Lei, WU Fangfang, FU Chunming.. Drug resistance analysis of Escherichia coli isolated from urinary tract infection in elder patients[J]. Laboratory Medicine, 2015, 30(12): 1206-1209.

Figures/Tables 2

References 14

[1]	CHOONG FX, REGBERG J, UDEKWU KI,et al.Intravital models of infection lay the foundation for tissue microbiology[J]. Future Microbiol, 2012, 7(4): 519-533.
[2]	李力, 白俊云, 符琴. 老年人泌尿系感染主要致病菌的耐药性分布[J]. 中国老年保健医学, 2009, 7(4): 107-108.
[3]	王平静, 阳江权, 崔荣恩. 老年泌尿系感染患者的临床治疗分析[J]. 临床合理用药杂志, 2014, 7(9): 88-89.
[4]	黄晓莉, 宋伶俐, 吴翠翠, 等. 老年泌尿系统感染患者病原菌分布及耐药性分析[J]. 中国老年学杂志, 2013, 33(14): 3465-3466.
[5]	王宝涵, 杨晓亚, 王新刚. 老年患者泌尿系感染的病原菌分布及耐药性分析[J]. 中华医院感染学杂志, 2011, 21(11): 2363-2365.
[6]	SILVA C, AFONSO N, MACÁRIO F, et al. Recurrent urinary tract infections in kidney transplant recipients[J]. Transplant Proc, 2013, 45(3): 1092-1095.
[7]	SÖRBERG M, FARRA A, RANSJÖ A, et al. Long-term antibiotic resistance surveillance of gram-negative pathogens suggests that temporal trends can be used as a resistance warning system[J]. Scand J Infect Dis, 2002, 34(5): 372-378.
[8]	陈中湘, 彭华, 刘培香, 等. 泌尿系感染的病原菌分布及大肠埃希菌耐药性分析[J]. 医学临床研究, 2014, 31(6): 1177-1178.
[9]	何娟妃, 陈群英, 何立忠, 等. 儿童泌尿系感染大肠埃希菌的耐药性分析[J]. 中国微生态学杂志, 2013, 25(1): 47-49.
[10]	卢怀民,于敬达. 老年患者大肠埃希菌耐药性的研究[J]. 包头医学院学报, 2013, 29(5): 35-36.
[11]	张永梅, 高建钢, 张志敏, 等. 内蒙地区老年人泌尿系感染耐药菌分布及耐药分析[J]. 内蒙古医科大学学报, 2013, 55(5): 350-353.
[12]	邓燕. 肾病综合征合并尿路感染39例临床分析[J]. 中国抗生素杂志, 2004, 29(9): 576-S1.
[13]	傅松雄, 董明国, 沈小文. 2 895例泌尿道感染患者病原菌分布及耐药性分析[J]. 检验医学, 2009, 24(6): 459-461.
[14]	National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing[S]. M100-S11, NCCLS, 2001.

抗菌药物	2011年8月至2012 年7月(233株)			2012年8月至2013 年7月(286株)			2013年8月至2014 年7月(318株)			合计(837株)			ESBLs阳性菌株 (525株)^*
抗菌药物	R	I	S	R	I	S	R	I	S	R	I	S	R	I	S
阿莫西林	93.1	0.0	6.9	93.4	0.3	6.3	89.9	0.6	9.4	92.0	0.4	7.6	100.0	0.0	0.0
哌拉西林	86.3	0.0	13.7	86.4	0.0	13.6	83.3	0.0	16.7	85.1	0.0	14.9	99.8	0.0	0.2
替卡西林	88.4	0.0	11.6	89.9	0.0	10.1	86.2	0.0	13.8	88.1	0.0	11.9	99.8	0.0	0.2
阿莫西林- 克拉维酸	8.6	26.2	65.2	14.3	26.6	59.1	8.5	32.1	59.4	10.5	28.7	60.8	13.7	41.0	45.3
哌拉西林- 克拉维酸	9.9	0.0	90.1	14.7	0.0	85.3	16.7	0.0	83.3	14.1	0.0	85.9	21.5	0.0	78.5
替卡西林- 克拉维酸	57.1	0.0	42.9	62.9	0.0	37.1	65.4	0.0	34.6	62.3	0.0	37.7	84.8	0.0	15.2
头孢噻吩	86.3	0.0	13.7	87.4	0.0	12.6	83.3	0.0	16.7	85.6	0.0	14.4	99.8	0.0	0.2
头孢呋辛	65.7	0.0	34.3	72.4	0.0	27.6	70.8	0.0	29.2	69.8	0.0	30.2	99.6	0.0	0.4
头孢他啶	57.1	0.4	42.5	68.9	0.0	31.3	64.5	0.0	35.5	63.9	0.1	36.0	99.4	0.0	0.6
头孢噻肟	57.1	0.4	42.5	68.9	0.0	31.1	64.5	0.0	35.5	63.9	0.1	36.0	99.4	0.2	0.4
头孢吡肟	57.1	0.0	42.9	68.9	0.0	31.1	64.5	0.0	35.5	63.9	0.0	36.1	99.4	0.0	0.6
头孢西丁	33.5	0.0	66.5	42.0	0.0	58.0	34.3	0.0	65.7	36.7	0.0	63.3	47.0	0.0	53.0
亚胺培南	0.0	0.0	100.0	0.0	0.0	100.0	0.0	0.0	100.0	0.0	0.0	100.0	0.0	0.0	100.0
美罗培南	0.0	0.0	100.0	0.0	0.0	100.0	0.0	0.0	100.0	0.0	0.0	100.0	0.0	0.0	100.0
阿米卡星	6.4	0.0	93.6	8.7	0.0	91.3	8.5	0.0	91.5	8.0	0.0	92.0	11.8	0.0	88.2
庆大霉素	53.6	0.4	45.9	53.1	0.0	46.9	51.6	0.0	48.4	52.8	0.1	47.1	60.2	0.2	39.6
奈替米星	27.0	0.0	73.0	31.5	0.0	68.5	34.3	0.3	65.4	31.5	0.1	68.4	41.0	0.2	58.9
妥布霉素	49.4	0.0	50.6	48.6	0.0	51.4	5.2	0.0	47.8	50.3	0.0	49.7	60.2	0.0	39.8
环丙沙星	78.5	0.0	21.5	86.4	0.3	13.3	77.0	1.3	21.7	80.7	0.6	18.7	91.4	0.4	8.2
复方磺胺甲口恶唑	59.2	0.0	40.8	57.0	0.0	43.0	43.4	0.0	56.6	52.6	0.0	47.4	57.1	0.0	42.9

抗菌药物	2011年8月至2012 年7月(233株)			2012年8月至2013 年7月(286株)			2013年8月至2014 年7月(318株)			合计(837株)			ESBLs阳性菌株 (525株)^*
抗菌药物	R	I	S	R	I	S	R	I	S	R	I	S	R	I	S
阿莫西林	93.1	0.0	6.9	93.4	0.3	6.3	89.9	0.6	9.4	92.0	0.4	7.6	100.0	0.0	0.0
哌拉西林	86.3	0.0	13.7	86.4	0.0	13.6	83.3	0.0	16.7	85.1	0.0	14.9	99.8	0.0	0.2
替卡西林	88.4	0.0	11.6	89.9	0.0	10.1	86.2	0.0	13.8	88.1	0.0	11.9	99.8	0.0	0.2
阿莫西林- 克拉维酸	8.6	26.2	65.2	14.3	26.6	59.1	8.5	32.1	59.4	10.5	28.7	60.8	13.7	41.0	45.3
哌拉西林- 克拉维酸	9.9	0.0	90.1	14.7	0.0	85.3	16.7	0.0	83.3	14.1	0.0	85.9	21.5	0.0	78.5
替卡西林- 克拉维酸	57.1	0.0	42.9	62.9	0.0	37.1	65.4	0.0	34.6	62.3	0.0	37.7	84.8	0.0	15.2
头孢噻吩	86.3	0.0	13.7	87.4	0.0	12.6	83.3	0.0	16.7	85.6	0.0	14.4	99.8	0.0	0.2
头孢呋辛	65.7	0.0	34.3	72.4	0.0	27.6	70.8	0.0	29.2	69.8	0.0	30.2	99.6	0.0	0.4
头孢他啶	57.1	0.4	42.5	68.9	0.0	31.3	64.5	0.0	35.5	63.9	0.1	36.0	99.4	0.0	0.6
头孢噻肟	57.1	0.4	42.5	68.9	0.0	31.1	64.5	0.0	35.5	63.9	0.1	36.0	99.4	0.2	0.4
头孢吡肟	57.1	0.0	42.9	68.9	0.0	31.1	64.5	0.0	35.5	63.9	0.0	36.1	99.4	0.0	0.6
头孢西丁	33.5	0.0	66.5	42.0	0.0	58.0	34.3	0.0	65.7	36.7	0.0	63.3	47.0	0.0	53.0
亚胺培南	0.0	0.0	100.0	0.0	0.0	100.0	0.0	0.0	100.0	0.0	0.0	100.0	0.0	0.0	100.0
美罗培南	0.0	0.0	100.0	0.0	0.0	100.0	0.0	0.0	100.0	0.0	0.0	100.0	0.0	0.0	100.0
阿米卡星	6.4	0.0	93.6	8.7	0.0	91.3	8.5	0.0	91.5	8.0	0.0	92.0	11.8	0.0	88.2
庆大霉素	53.6	0.4	45.9	53.1	0.0	46.9	51.6	0.0	48.4	52.8	0.1	47.1	60.2	0.2	39.6
奈替米星	27.0	0.0	73.0	31.5	0.0	68.5	34.3	0.3	65.4	31.5	0.1	68.4	41.0	0.2	58.9
妥布霉素	49.4	0.0	50.6	48.6	0.0	51.4	5.2	0.0	47.8	50.3	0.0	49.7	60.2	0.0	39.8
环丙沙星	78.5	0.0	21.5	86.4	0.3	13.3	77.0	1.3	21.7	80.7	0.6	18.7	91.4	0.4	8.2
复方磺胺甲口恶唑	59.2	0.0	40.8	57.0	0.0	43.0	43.4	0.0	56.6	52.6	0.0	47.4	57.1	0.0	42.9

[1]	PAN Fen, PAN Yuxuan, SHI Yingying, YU Fangyuan, ZHANG Hong. UroQuick rapid urine culture technique for urinary tract infection in children [J]. Laboratory Medicine, 2022, 37(7): 652-656.
[2]	SHANG Xipeng, LI Sha, DU Jinghui, LIU Xu. Research status of Actinotignum schaalii [J]. Laboratory Medicine, 2022, 37(4): 392-395.
[3]	WEN Qinghui, LI Fengying, LI Yanchang, HUANG Jinyin, WANG Fengping. Drug susceptibility of multidrug-resistant ESBL-producing Escherichia coli to antimicrobial agents restored by different concentrations of EDTA [J]. Laboratory Medicine, 2022, 37(3): 205-208.
[4]	PAN Yunqi, LI Yungai, WANG Jianqiang, WU Qiong, TANG Jin. Analysis of molecular typing,virulence genes and antibiotic susceptibility of uropathogenic Escherichia coli in patients with recurrent urinary tract infection [J]. Laboratory Medicine, 2022, 37(2): 141-145.
[5]	KANG Yi, ZHU Hong, SHEN Han, ZHOU Wanqing. Virulence gene analysis of Enterococcus isolated from clinical blood and urine samples [J]. Laboratory Medicine, 2022, 37(11): 1030-1033.
[6]	XIAO Nan, ZHOU Jia, DUAN Ning, ZHU Tianyang, WANG Lijun. Establishment and evaluation of fast predictive algorithm for urinary tract infection pathogen in patients with nephrolithiasis [J]. Laboratory Medicine, 2021, 36(1): 75-79.
[7]	LU Xiufen, HE Zhijun, LIU Qiting, FENG Zhongxin, MA Sheng. Serum procalcitonin and urine endotoxin determinations for guiding CAUTI antimicrobial therapy [J]. Laboratory Medicine, 2020, 35(7): 686-690.
[8]	LIU Yan, LONG Yin, PAN Weijie, ZHANG Tong, WENG Wenhao, YU Ying. Role of fecal DNA level of Fusobacterium nucleatum and clbA+ Escherichia coli in the diagnosis of colorectal cancer [J]. Laboratory Medicine, 2020, 35(4): 314-317.
[9]	GAO Juyi, WU Chuanan, YANG Weikang, LUO Yuxuan, LIU Shengnan, XU Xiaoping. Role of COP microfluidic chip for the rapid detection of Escherichia coli O157:H7 [J]. Laboratory Medicine, 2020, 35(2): 148-152.
[10]	YANG Meiling, LIU Hao, YANG Lin, ZHU Ping. Research progress on the biomarkers of urinary tract infection [J]. Laboratory Medicine, 2020, 35(2): 178-180.
[11]	LIU Cunfen, WANG Yan, YANG Rong, HU Lixiang. Relationship between ESBL genotyping of Escherichia coli and integron in Anning [J]. Laboratory Medicine, 2020, 35(12): 1263-1266.
[12]	MALDI-TOF MS SHEN Zhenhua, CHEN Rong. Performance evaluation for the direct detection of pathogenic bacteria causing urinary tract infection by [J]. Laboratory Medicine, 2019, 34(5): 447-450.
[13]	WANG Xiaolong, HUANG Zuofu, ZHANG Shuxia, YANG Yulin. Bloodstream infection and pathogen drug resistance in hemodialysis patients [J]. Laboratory Medicine, 2018, 33(8): 711-715.
[14]	LI Caiqing, CAO Jing, ZHAN Minghua, HAN Xuying, LI Xiaofeng, LIU Jinlu. Relationship between Corynebacterium urealyticum and the formation of ammonium magnesium phosphate crystals in urine [J]. Laboratory Medicine, 2018, 33(5): 384-387.
[15]	YU Peijuan, ZHANG Gaolin, YAN Ruhong, FENG Ping, SUN Lanyun, ZHU Xueming, WANG Jinghua. Urinary sediment analysis combined with serum procalcitonin determination in the diagnosis of urinary tract infection [J]. Laboratory Medicine, 2018, 33(4): 299-304.